| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TIG1 |
| Entrez GeneID | 5918; |
| WB Predicted band size | 26kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to a region derived from internal residues of human Retinoic acid receptor responder (tazarotene induced) 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于RARRES1抗体的3篇示例文献概览(注：文献为示例性描述，仅供参考格式)：
---
1. **文献名称**: *RARRES1 suppresses melanoma progression through Wnt/β-catenin signaling inhibition*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种针对RARRES1的单克隆抗体，证实其在黑色素瘤组织中表达下调。通过抗体介导的功能实验，发现RARRES1通过抑制Wnt/β-catenin通路抑制肿瘤迁移和侵袭。
2. **文献名称**: *RARRES1 as a prognostic biomarker in breast cancer: Immunohistochemical analysis using a novel polyclonal antibody*
**作者**: Lee J, et al.
**摘要**: 作者制备了兔源多克隆RARRES1抗体，并通过免疫组化分析乳腺癌组织样本。结果显示，RARRES1低表达与患者生存率降低显著相关，提示其作为预后标志物的潜力。
3. **文献名称**: *Secreted RARRES1 modulates macrophage polarization in chronic inflammation*
**作者**: Zhang Y, et al.
**摘要**: 该研究利用抗RARRES1中和抗体，发现分泌型RARRES1通过调控TLR4信号通路促进M1型巨噬细胞极化，揭示了其在炎症微环境中的调控机制。
---
以上示例展示了RARRES1抗体在不同研究场景中的应用，包括肿瘤机制探索、预后标志物开发及免疫调控研究。实际文献需通过学术数据库检索获取。
RARRES1 (Retinoic Acid Receptor Responder 1), also known as TIG1 or HHCM22. is a transmembrane protein encoded by the *RARRES1* gene. It belongs to the retinoid-inducible gene family and is implicated in diverse cellular processes, including lipid metabolism, differentiation, apoptosis, inflammation, and cancer progression. Structurally, RARRES1 contains a conserved lipid-binding domain (lipocalin-like fold) and may function as an adipokine or signaling molecule in metabolic regulation. Its expression is regulated by retinoic acid (RA) and peroxisome proliferator-activated receptors (PPARs), linking it to pathways involved in energy homeostasis and immune modulation.
Antibodies targeting RARRES1 are essential tools for studying its physiological and pathological roles. Polyclonal and monoclonal RARRES1 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA to detect protein expression, localization, and post-translational modifications. These antibodies help elucidate RARRES1's dual roles in cancer—acting as both a tumor suppressor (e.g., in prostate and liver cancers) and a promoter of metastasis (e.g., in melanoma) by modulating tumor-stroma interactions, extracellular matrix remodeling, or immune evasion. Additionally, RARRES1 antibodies aid in exploring its involvement in metabolic disorders, such as obesity and insulin resistance, where altered RARRES1 levels correlate with adipose tissue dysfunction.
Challenges in antibody development include ensuring specificity due to RARRES1's glycosylation and potential splice variants. Validated antibodies are critical for clarifying its context-dependent functions and therapeutic potential in precision medicine.
×
